Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPD1 | P10809 | 2/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | XPO1 | O14980 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | F12 | P00748 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446526 | 0.88 | KDR (0.60) | KDRSORT1ALDH1A1NPC1RAB9A | |
| SCHEMBL985881 | 0.85 | LRRK2 (0.53) | HSPD1HSPE1HTTALDH1A1NPC1 | |
| SCHEMBL2637005 | 0.82 | PRKCI (0.60) | HSPD1HSPE1SORT1ALDH1A1KDM4E | |
| SCHEMBL12074815 | 0.82 | KDR (0.50) | KDRUSP2HTTTMPRSS4XPO1 | |
| SCHEMBL759085 | 0.78 | MAOA (0.53) | HTTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL984274 | 0.78 | EPHB3 (0.50) | KDRHTTALDH1A1KDM4ENPC1 | |
| SCHEMBL4967520 | 0.77 | RAB9A (0.53) | KDRHTTSORT1ALDH1A1NPC1 | |
| SCHEMBL15999441 | 0.76 | OPRK1 (0.46) | KDRSORT1KMT2AEGFR | |
| SCHEMBL1910338 | 0.76 | ALDH1A1 (0.68) | KDRALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL985376 | 0.76 | TP53 (0.46) | KDRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2125780-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008141385-A1 | VIRAL POLYMERASE INHIBITORS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-11-27 | — | — | WO | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200464-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | HSPD1 2271/4885HSPE1 1192/4885KDR 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.